Log in

FRA:MRKMerck KGaA Stock Price, Forecast & News

€106.85
-0.15 (-0.14 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
€106.40
Now: €106.85▼
€108.35
50-Day Range
€99.62
MA: €104.06▼
€107.55
52-Week Range
€76.60
Now: €106.85▼
€115.00
Volume442,531 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. The company also provides life science products and services for use in the discovery, development, and manufacture of drug therapies, as well as in laboratories; and specialty chemicals for use in displays, computer chips, surfaces, Integrated circuits, microelectronic systems, anti-reflection coatings, and cosmetics. It has alliances with Pfizer Inc., Bristol-Myers Squibb Company, Intrexon Corporation, Avillion LLP., F-star Delta Ltd, SFJ Pharmaceuticals Group, Alibaba Health, Checkmate Pharmaceuticals, Solvias, and Leap Therapeutics, Inc., as well as a collaboration with Daiichi Sankyo Company, Limited. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
Read More
Merck KGaA logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.86 out of 5 stars


Industry, Sector and Symbol

Stock Exchange FRA
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolFRA:MRK
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.merckgroup.com
Phone+49-6151-720

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees51,039
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableOptionable
MRK Rates by TradingView

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Merck KGaA (FRA:MRK) Frequently Asked Questions

How has Merck KGaA's stock been impacted by COVID-19 (Coronavirus)?

Merck KGaA's stock was trading at €98.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRK shares have increased by 8.3% and is now trading at €106.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Merck KGaA?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 3 sell ratings, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Merck KGaA.

What price target have analysts set for MRK?

15 analysts have issued 1 year price objectives for Merck KGaA's shares. Their forecasts range from €90.00 to €125.00. On average, they expect Merck KGaA's stock price to reach €108.50 in the next year. This suggests a possible upside of 1.5% from the stock's current price. View analysts' price targets for Merck KGaA.

Has Merck KGaA been receiving favorable news coverage?

Media stories about MRK stock have trended somewhat negative on Saturday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merck KGaA earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the healthcare company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about Merck KGaA.

Who are some of Merck KGaA's key competitors?

What other stocks do shareholders of Merck KGaA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck KGaA investors own include Micron Technology (MU), Abbott Laboratories (ABT), Cisco Systems (CSCO), NVIDIA (NVDA), Boeing (BA), Pluristem Therapeutics (PSTI), QUALCOMM (QCOM), HDFC Bank (HDB), IBM (IBM) and Johnson & Johnson (JNJ).

Who are Merck KGaA's key executives?

Merck KGaA's management team includes the following people:
  • Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
  • Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
  • Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
  • Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
  • Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)

What is Merck KGaA's stock symbol?

Merck KGaA trades on the FRA under the ticker symbol "MRK."

What is Merck KGaA's stock price today?

One share of MRK stock can currently be purchased for approximately €106.85.

What is Merck KGaA's official website?

The official website for Merck KGaA is www.merckgroup.com.

How can I contact Merck KGaA?

Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.